Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Paul A. S. Fishkin"'
Autor:
Ajay Major, Justin Kline, Theodore G. Karrison, Paul A. S. Fishkin, Amy S. Kimball, Adam M. Petrich, Sreenivasa Nattam, Krishna Rao, Bethany G. Sleckman, Kenneth Cohen, Koen van Besien, Aaron P. Rapoport, Sonali M. Smith
Publikováno v:
Haematologica, Vol 107, Iss 7 (2021)
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the
Externí odkaz:
https://doaj.org/article/da69c238a67c488eac97c5b0995a9e46
Autor:
Adam M. Petrich, Koen van Besien, Justin Kline, Krishna Rao, Sreenivasa Nattam, Ajay Major, Amy S. Kimball, Aaron P. Rapoport, Kenneth J. Cohen, Bethany G. Sleckman, Sonali M. Smith, Theodore Karrison, Paul A. S. Fishkin
Publikováno v:
Haematologica. 107(7)
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the
Autor:
Stephen J. Schuster, Paul A. S. Fishkin, Thomas M. Habermann, Lode J. Swinnen, Michael E. Williams, Fangxin Hong, W. Christopher Ehmann, Christopher Peterson, Brad S. Kahl, Timothy S. Fenske, Matthias Weiss
Publikováno v:
Blood. 138:815-815
BACKGROUND: E4402 was a randomized phase III study comparing two different rituximab dosing strategies for patients with previously untreated, low tumor burden follicular lymphoma (FL). The primary endpoint was time to treatment failure. The initial
Autor:
Ajay Major, Justin Kline, Kenneth J. Cohen, Adam M. Petrich, Amy S. Kimball, Bethany G. Sleckman, Koen van Besien, Paul A. S. Fishkin, Aaron P. Rapoport, Theodore Karrison, Sreenivasa Nattam, Sonali M. Smith
Publikováno v:
Blood. 136:43-44
Background Targeting the PI3K/Akt/mTOR axis in relapsed lymphomas is of interest based on constitutive activation in many lymphoma subtypes, and has had varying degrees of success. We previously showed that the first generation mTOR inhibitor, temsir
Autor:
Balazs Halmos, James Suh, Jane Liu, Manuel Doria, Jeffrey S. Ross, Sai-Hong Ignatius Ou, K. Cynthia Hsieh, Ranee Mehra, Vincent A. Miller, James A. Knost, Paul A. S. Fishkin, Philip J. Stephens, Garrett M. Frampton, Steven C. Buck, Alexa B. Schrock, Nir Peled, Nagla Abdel Karim, Siraj M. Ali, Jose A. Bufill, Rong Chen, Eduardo Braun, Shuyu D. Li
Publikováno v:
Journal of Thoracic Oncology. 12:932-942
Pulmonary sarcomatoid carcinoma (PSC) is a high-grade NSCLC characterized by poor prognosis and resistance to chemotherapy. Development of targeted therapeutic strategies for PSC has been hampered because of limited and inconsistent molecular charact
Autor:
R. Donald Harvey, Bradley C. Carthon, Cody J. Peer, Abiola Ibraheem, Wei Peng Yong, Elia Martinez, Russell Z. Szmulewitz, Paul A. S. Fishkin, Mark J. Ratain, Chadi Nabhan, Mark Kozloff, Edmund Chiong, Theodore Karrison, Walter M. Stadler, William D. Figg
Purpose Abiraterone acetate (AA) is a standard of care for metastatic castration-resistant prostate cancer (CRPC). Despite a large food effect, AA was administered under fasting conditions in its pivotal trials. We sought to test the hypothesis that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfe416710ed0875ee7491b7b85e49a9e
https://europepmc.org/articles/PMC5941614/
https://europepmc.org/articles/PMC5941614/
Autor:
Betsy LaPlant, B. S. Lair, Thomas E. Witzig, Paul A. S. Fishkin, Matthew T. Drake, David J. Inwards, Paul J. Kurtin, Donald B. Wender, Daniel A. Nikcevich
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 30(2)
Abstract 3661 Objective: We conducted this trial to determine the maximum tolerated dose (MTD) and schedule of temsirolimus added to an established regimen comprised of rituximab and cladribine for the initial treatment of mantle cell lymphoma and to
Autor:
Russell Z. Szmulewitz, Walter M. Stadler, Gregory S. Karczmar, Aytekin Oto, Peter H. O'Donnell, Shannon Towey, Randy F. Sweis, Milica Medved, Paul A. S. Fishkin, Theodore Karrison
Introduction/Background Traditional imaging assessment criteria might not correlate well with clinical benefit from vascular endothelial growth factor pathway-directed therapy in metastatic renal cancer. Preclinical data suggest tumor growth is prece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a1ff66963e5981fbe57bb92efc1c39c
https://europepmc.org/articles/PMC5315677/
https://europepmc.org/articles/PMC5315677/
Publikováno v:
Cureus
Epidermal growth factor receptor (EGFR) mutations and anaplastic large-cell lymphoma kinase (ALK) rearrangements are now routine biomarkers that have been incorporated into the practice of managing non-small cell lung cancer (NSCLC). Historically, th
Autor:
Patrick J. Flynn, Tom R. Fitch, Muhammad Salim, Edith A. Perez, Winston Tan, Albert M. Bernath, Philip J. Stella, Jacob B. Allred, Martin Wiesenfeld, Paul A. S. Fishkin
Publikováno v:
Clinical Breast Cancer. 12:81-86
Background We conducted a multiinstitutional phase II study of capecitabine in combination with vinorelbine and trastuzumab in patients eligible to receive first- or second-line treatment for human epidermal growth factor receptor type 2 (HER2)-posit